Becton Dickinson (BDX) has gained 1.2% to $101.97 this morning after�Piper Jaffray�raised the stock to Overweight from Neutral. Analysts�William Quirk and�David Clair�explain why they’re optimistic about the medical technology company:
Associated PressObservations from multiple diagnostic conferences all suggest significant interest in�microbiology investment. This interest spans track systems (Kiestra), new identification�technologies (Maldi/BioTyper) and Molecular (gram +/- assays). When considering�AST (antimicrobial susceptibility testing) recall from Siemens, we believe BD’s�microbiology business is poised to accelerate its performance over the next several years.�Combined with a delayed JNJ/Ypsomed pen needle launch and incremental European�safety adoption, we believe numbers for BD will continue to climb…
5 Best Insurance Stocks To Invest In Right Now: Enanta Pharmaceuticals Inc (ENTA)
Enanta Pharmaceuticals, Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. The Company is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes-protease (partnered with AbbVie, the former research-based pharmaceutical business of Abbott Laboratories), NS5A (partnered with Novartis) and nucleotide polymerase, as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. ABT-450, discovered through its collaboration with AbbVie, is a protease inhibitor that has demonstrated in vitro potency against known resistant HCV mutants.
In Phase I studies, ABT-450 co-administered with ritonavir, a commonly used boosting agent to increase the blood concentrations of many protease inhibitors, was shown to be safe and well tolerated. Co-administration of ABT-450 with ritonavir, which it refers to together as ABT-450/r, has enabled once-daily dosing of ABT-450. Phase II studies have demonstrated the efficacy of ABT-450/r in patients with chronic HCV, and other interferon-free Phase II studies of ABT-450-containing regimens continue. AbbVie is developing a next-generation protease inhibitor discovered within the Enanta-AbbVie collaboration. EDP-239 is the NS5A inhibitor discovered by the Company. The Company also has a program to develop nucleotide inhibitors to HCV NS5B polymerase, which is another DAA mechanism considered to have a barrier to resistance. The Company�� Bicyclolide antibiotic product candidate is EDP-788, which it is developing for use as an intravenous drug in the hospital setting and for oral dosing in the home setting. EDP-788 is a prodrug, which means that it is inactive until it is converted in the body into an active compound. EDP-788 is! a water-soluble molecule which, when administered in preclinical models, is cleanly and rapidly converted into the active compound.
Advisors' Opinion:- [By James Fink]
And lastly I'll go into healthcare, which is kind of a growth cyclical type name. It's partially defensive, partially growth. I think the more growth-oriented section of healthcare would be biotech, and right now, a very promising biotech stock is Enanta Pharmaceuticals. That's a NASDAQ stock; ticker symbol (ENTA).
- [By Sean Williams]
The next big thing in treating hepatitis-C
The other currently experimental therapy very likely to make it onto the FDA's desk before the midpoint of 2014 is AbbVie's (NYSE: ABBV ) direct-acting antiviral combo drug. In similar fashion to Sovaldi, this DAA-combo therapy, which includes ABT-450 from Enanta Pharmaceuticals (NASDAQ: ENTA ) , is running six confirmatory late-stage trials on various genotypes. There are, however, two primary differences between AbbVie's DAA-combo therapy and Sovaldi. - [By George Budwell]
Normally, such strong efficacy results would be hailed as a major achievement. However, these results are actually less impressive than those by competing drug's developed by AbbVie (NYSE: ABBV ) , Enanta Pharmaceuticals (NASDAQ: ENTA ) and Gilead. Bristol-Myers' therapy also has a treatment duration double that of Gilead's drug Sovaldi for genotype 1 patients. So, while these results are impressive in their own right, the therapy's commercial prospects may be limited due to the presence of superior competitors in the market.�
Top Medical Companies To Buy For 2014: Taro Pharmaceutical Industries Ltd (TARO)
Taro Pharmaceutical Industries Ltd., incorporated in 1959, is a science-based pharmaceutical company. The Company develops manufactures, and markets prescription and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. The Company also develops and manufactures active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Company�� primary areas of focus include pediatric creams and ointments, liquids, capsules and tablets, mainly in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The Company operates through three companies: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries (including indirect), Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets more than 180 pharmaceutical products in over 25 countries.
Taro Israel manufactures more than 160 finished dosage form pharmaceutical products for sale in Israel and for export. It produces APIs used in the manufacture of finished dosage form pharmaceutical products. It markets and distributes generic products in the local Israeli market. Taro Israel�� primary product lines include dermatology, prescription and OTC semi-solid products (creams, ointments and gels) and liquids; cardiology and neurology, prescription oral dosage products; oral analgesics, both prescription and OTC, and OTC oral and nasal sprays and ophthalmic products.
Taro Canada manufactures more than 70 finished dosage form pharmaceutical products for sale in Canada and for export. It markets and distributes generic products in the local Canadian market. Its product line includes dermatology: prescription and OTC semi-solid products (creams, ointments and gels) and liquids, cardiology, oncology, gastrointestinal and neurology: prescription oral and injects able dosage products, and allergy (antihistamine): OTC oral dosage products.
Taro U.S.A markets! and distributes generic products in the United States market. Its primary product lines include dermatology: prescription and OTC semi-solid products (creams, ointments and gels) and liquids, cardiology and neurology: prescription oral dosage products, and other prescription and OTC products.
The Company competes with Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer/Wyeth, Valeant, Galderma, Merck/Schering-Plough, Teva Pharmaceuticals U.S.A., Mylan Laboratories, Perrigo Company, Ranbaxy Pharmaceuticals Inc., Sandoz Pharmaceuticals, Merck Canada Inc., Pfizer Canada Inc., Janssen Inc., Schering-Plough Canada, Novartis Pharmaceuticals Canada Inc., GlaxoSmithKline Inc., Bayer Inc., Bristol-Myers Squibb Canada, Apotex Inc., Teva Canada Limited, Mylan Pharmaceuticals ULC, Sandoz Canada Incorporated, Pharmascience Inc., Teva Pharmaceutical Industries Ltd., Perrigo Israel Pharmaceuticals Ltd., Dexxon Ltd., Rafa Laboratories Ltd., Bayer AG, Eli Lilly and Company, Merck & Co., Inc. and Pfizer Inc.
Advisors' Opinion:- [By Rich Smith]
Israeli drugmaker Taro Pharmaceutical Industries (NYSE: TARO ) has a new CEO -- and a new Chairman of the Board, as well.
On Thursday, Taro announced the imminent retirement of Interim Chief Executive Officer Mr. James Kedrowsk, who will be replaced August 1 by new permanent CEO Mr. Kalyanasundaram Subramanian ("Kal Sundaram"). Additionally, the company said that Dilip Shanghvi�has been appointed Chairman of its Board of Directors.
Top Medical Companies To Buy For 2014: Digirad Corp (DRAD)
Digirad Corporation, incorporated in 1997, is the developer and manufacturer of medical diagnostic imaging systems, including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications. The Company operates in two segments: DIS (its diagnostic imaging service business) and its product segment. Through DIS, the Company provides in-office imaging services to physicians, offering certified personnel, required licensure, an imaging system and other support and supplies for the performance of nuclear and ultrasound imaging procedures under the supervision of its physician customers. The Companies imaging systems are sold in both portable and fixed configurations. DIS physician customers enter into annual lease contracts for imaging services generally delivered on a per-day basis. The Company�� product segment sells solid-state gamma cameras and provides camera service and maintenance.
Imaging Services
DIS offers portable nuclear and ultrasound imaging services. Its nuclear modality services include an imaging system, a certified nuclear medicine technologist and a cardiac stress technician, often certified or a trained nurse or paramedic, the supply of radiopharmaceuticals, and required licensing services for the performance of nuclear imaging procedures under the supervision of physicians. The ultrasound imaging service is similar, in that the Company provides the ultrasound equipment and one ultrasound technologist. Its portable nuclear imaging operations use a hub and spoke model, in which centrally located regional hubs anchor multiple van routes in the surrounding metropolitan areas. At its DIS hubs, clinical personnel load the equipment, radiopharmaceuticals, and other supplies onto specially equipped vans for transport to the physician�� office or other customer locations, where they set up the equipment for the day. The Company provides nuclear and ultrasound services primarily under annual contracts for services delivered on a per-day ! basis.
Products
Digirad markets and manufactures a line of nuclear medicine cameras for nuclear cardiology and general nuclear medicine applications. Its cameras are used in hospitals, imaging centers, physician offices and by mobile service providers. Its nuclear cameras feature detectors based on solid-state technology developed by the Company. The solid-state technology provides the Company with the capability to market and manufacture a diverse family of cardiac and general-purpose cameras.
The Cardius family of cardiac SPECT (single-photon emission computerized tomography) solid-state imagers makes it possible to image patients up to 500 pounds in a sitting position. Upright imaging makes it possible to image bariatric, COPD (chronic obstructive pulmonary disease) or claustrophobic patients that typically could not be imaged lying down on. The Company offers fixed dual-head and triple-head cardiac camera models for use within a facility and a portable dual-head configuration that makes it possible to move the system to provide service to multiple rooms or sites. Its flagship in cardiology is the Cardius XACT SPECT/CT system. It features a triple-head design and a low dose volume computed tomography (CT) attenuation correction methodology.
The Company�� ergo is a large-field-of-view planar portable imaging camera. The ergo imaging system is targeted to hospitals with multi-camera general nuclear medicine departments, academic centers, pediatric hospitals, regional trauma centers, women�� health centers and cancer centers. The Company also provides triple-head Cardius 3 XPO system, which provides shorter image acquisition time. Its Cardius X-ACT camera is a rapid cardiac SPECT/VCT imager. The Cardius X-ACT camera is positioned more toward the hospital and larger cardiology practices.
Advisors' Opinion:- [By Lisa Levin]
Digirad (NASDAQ: DRAD) shares created a new 52-week high of $3.989 on Q3 results.
Posted-In: 52-Week HighsNews Intraday Update Markets Movers
Top Medical Companies To Buy For 2014: Applied Nanotech Holdings Inc (APNT)
Applied Nanotech Holdings, Inc., incorporated on May 22, 1989, is engaged in nanotechnology research and development business. The Company's nanotechnology research involves performing contract research and development services for others to develop products and materials for new applications, and then leveraging this research by applying it to other similar applications in other industries. The Company also develops intellectual property (IP) around its products and technologies. The Company develops five technology platforms: nanosensor technology; nanocomposites, based on carbon nanotube composites; thermal management materials; nanoelectronics applications, and electron emission activities, primarily in the display area. The Company's electron emission IP is divided into display activities and non-display activities. Applied Nanotech Holdings, Inc. is the parent company. Applied Nanotech, Inc. (ANI) is a subsidiary of ANHI. During the year ended December 31, 2012, the Company formed EZDiagnostix, Inc., (EZDX).
Sensors
The Company develops sensors based on ion mobility sensor technology and differential mobility spectroscopy. The Company is involved in projects to develop Mercaptan and Methane sensors for uses in the natural gas industry. The Company is also applying this technology to other applications, including agricultural pathology, wound care, and breath analysis. The Company develops hydrogen sensor for use in the measurement of hydrogen in power transformer products. The Company develops carbon monoxide sensor that can last for 10,000 hours on a single battery. The Company's carbon nanotube technology is for use in biosensors. Sensors based on carbon nanotubes or other nanomaterials can be used to detect chemical, organic, or biological warfare agents, as well as explosives, hydrogen, ammonia and numerous other chemicals.
Nanocomposites
The Company is in the advanced stages of development of nanomaterials using carbon nanotube (CNT) and! other composites. Epoxies are used in industries with worldwide markets, with applications, including adhesives, paints, coatings, and composites. In addition to epoxy resins, the Company develops other types of resins, including polyesters and vinyl esters. Vinyl esters are used in a variety of industrial applications, including storage tanks, piping, and construction. The Company develops a process for coating nylon pellets with CNTs to improves electrical conductivity. Nylon 6 with improved electrical conductivity can be used for its anti-static qualities, electrostatic discharge, and electromagnetic/RF shielding.
Thermal Management
The Company markets thermal management material called CarbAl. CarbAl provides a passive thermal management solution for temperature control issues that plague electronics manufacturers. CarbAl is a carbon based metal nanocomposite comprised of 80% carbonaceous matrix and a dispersed metal component of 20% aluminum. The Company also develops a simplified version of CarbAl based on graphite.
Conductive Inks
The Company develops aluminum and silver inks and pastes that is ideal for use in the production of solar cells. The Company also develops aluminum paste that can be used in current solar cell production.
The Company competes with Zyvex Performance Materials, GSI Creos, Amroy Europe, Ltd., DuPont and Ferro
Advisors' Opinion:- [By Anuchit Nguyen]
India�� S&P BSE Sensex rose, holding at a three-year high, amid better-than-estimated corporate earnings. Engineering company Larsen & Toubro Ltd. (LT) rallied to a three-month high and Asian Paints Ltd. (APNT) surged about 6 percent after reporting profit that beat forecasts.
Top Medical Companies To Buy For 2014: Evolva Holding SA (EVE)
Evolva Holding SA (Evolva) discovers and provides ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create small molecule compounds and their production routes. The Company�� nutrition and consumer products include Pomecins, saffron, stevia, vanilla and resveratrol. The Company�� pharmaceuticals products include EV-077 and EV-035. In pharmaceuticals, the Company focuses on oral, small molecule drugs with application in complications of diabetes and infectious diseases. Pomecins are Evolva�� compounds. Evolva is focused on two members of the family - Pomecin A and Pomecin B. EV-035 is a bacterial type II topoisomerase inhibitor. Evolva is developing EV-077 for the treatment of diabetic complications. It is an oral, small molecule compound, belonging to a structural class. Advisors' Opinion:- [By Glenwoods]
Earlier this year the giant food processor, Cargill, partnered with the small Swiss company, Evolva (SIX:EVE), which was developing its own stevia-based fermentation process, also in the pilot stage. As noted earlier in the article, Cargill is in a partnership with Coca-Cola for Truvia, the bestselling stevia product on the market. The success of the Cargill/Evolva partnership could have big implications not just for Cargill and Coca-Cola, but also on the entire stevia and sweetener market. I further believe the success of the partnership could have a major impact on Stevia First. If Cargill�� fermentation method produces a better tasting stevia product at a lower cost it would give Coca-Cola a considerable advantage over the other beverage bottlers, food manufacturers, and stevia producers. Such an outcome would force these companies to scramble to find a similar method in order to compete. There would be a very good chance that rival companies, in order to stay in the game, would have to turn to the other company developing a fermentation-based stevia product-- Stevia First. If that happens Stevia First�� value would rise considerably.
Top Medical Companies To Buy For 2014: Spectrum Pharmaceuticals Inc.(SPPI)
Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company, primarily focuses on oncology and hematology. The company engages in acquiring, developing, and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. It markets Zevalin, a prescribed form of cancer therapy, radioimmunotherapy; and Fusilev, a novel folate analog formulation and the pharmacologically active isomer of the racemic compound, calcium leucovorin. The company?s drugs in late stage development include Apaziquone, an anti-cancer agent; and Belinostat, a histone deacytelase inhibitor. Its drugs in development also include Ozarelix a luteinizing hormone releasing hormone antagonist, which is in Phase II clinical stage; SPI-1620, a peptide agonist of endothelin B receptors, which is in Phase I clinical stage; and RenaZorb, a lanthanum-based nanoparticle phosphate binding agent, which is in preclinical stage. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.
Advisors' Opinion:- [By Rich Smith]
Spectrum Pharmaceuticals (NASDAQ: SPPI ) has found itself a new Executive Vice President, a new Chief Financial Officer, and a new Principal Accounting�Officer. They're all the same person.
- [By James E. Brumley]
Eight months ago, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) was a train wreck. Shares had plunged from $12.43 to $7.79 on the heels of bad news, and SPPI wouldn't stop bleeding until it hit a low of $6.92 a few days after the big selloff. That bad news? A warning that its full-year sales (and particularly sales of its cancer drug Fusilev) would be well short of expectations.
- [By Jake L'Ecuyer]
Spectrum Pharmaceuticals (NASDAQ: SPPI) shares tumbled 9.77 percent to $8.18 after the company announced an offering of $100 million of convertible notes.
No comments:
Post a Comment